Narrow Pathways for Clinical-Stage Companies Without Sales

The National Growth Fund, into which the government plans to invest 150 trillion won over five years, is now in operation and was expected to channel capital into the bio sector, one of the pillars of advanced strategic industries. However, participation from new drug development companies remains minimal. The fund's capital appears to be concentrated among companies that already have large-scale production facilities, such as contract development and manufacturing organizations (CDMOs) and vaccine manufacturers.


According to the industry on May 27, there has been a series of cases where bio companies, which had anticipated large-scale capital injections, have withdrawn after reviewing the eligibility requirements for support from the National Growth Fund. The CEO of a KOSDAQ-listed bio company commented, "It is difficult for small companies, and only large conglomerate affiliates or sizable pharmaceutical companies can truly benefit from this system."


The National Growth Fund is a public-private financial support initiative that was launched in December of last year. Combining 75 trillion won in government funds and 75 trillion won in private capital, its goal is to foster advanced strategic industries—including semiconductors, artificial intelligence (AI), and bio—over five years. The support is divided into four categories: 50 trillion won in low-interest loans, 15 trillion won in direct investment, 35 trillion won in indirect investment, and 50 trillion won in infrastructure investment. Although the initial plan was to raise 600 billion won annually over five years, surging demand has led the Financial Services Commission to consider increasing the allocation in the second half of the year.


National Growth Fund: Out of Reach for Biotech Companies View original image

Industry observers point out that the National Growth Fund's support criteria for the bio field focuses more on the size of existing production facilities—'current capability'—rather than the potential or capacity for new drug development. According to the recently released guidebook from the Financial Services Commission, the Restriction of Special Taxation Act, which underpins support for bio companies, recognizes a broad range of activities from the discovery of new drug candidates to clinical trials Phases 1, 2, and 3. New drug companies and small-scale ventures are eligible under this track.


The issue lies with another provision: the National Advanced Strategic Industries Act. This law narrows the scope of bio support technologies to "large-scale cultivation/production of 10,000 liters or more," making it difficult for companies that are not major CDMOs to qualify. While new drug companies can only rely on the tax law track, large CDMOs benefit from an additional production facility track. The same applies to vaccines. Since the support targets not just clinical trials but also the development and manufacture of raw materials, components, and production equipment, companies with established production infrastructure are at a clear advantage.


If eligibility requirements are strict, the next avenue is the method of financial support, but here too the balance tips toward production companies. The primary tool, low-interest loans, requires repayment of principal and interest, so the fund naturally favors companies that can demonstrate the ability to repay their debts. This means companies must provide evidence of contracts guaranteeing future revenue and show that operating profits can cover debt service.


In addition, companies must initially cover 20 to 50 percent of project costs with their own funds. Direct investments, which are recouped by selling equity stakes, also favor companies with clear sales or exit prospects. For CDMOs that already generate sales through contract manufacturing of pharmaceuticals, these conditions are not difficult to meet. However, for new drug companies still at the clinical stage—without product sales or substantial internal funds—these are significant hurdles.


This structure was evident in the first support case. On April 30, the National Growth Fund's Fund Management Deliberation Committee approved a long-term, low-interest loan of 85 billion won for Vtgen (formerly STgenBio) to expand its biosimilar production facilities in Songdo, Incheon. This company, which performs contract manufacturing of Dong-A ST's biosimilar Imyuldosa, has an established sales base. The first recipient to meet both eligibility and financial requirements turned out to be a production company.


It is not that the National Growth Fund has completely closed the door to new drug companies. The government has divided responsibilities so that the Ministry of SMEs and Startups' Korea Venture Investment Corp. handles support for early-stage and venture companies, while large-scale facility investments fall under the National Growth Fund. For new drug companies, the intended pathway is not loans but indirect investment. If there is a promising investment opportunity in a ministry-led bio fund, the National Growth Fund will co-invest; for technologies with long commercialization periods, a super-long-term technology investment fund with a lifespan of more than 10 years will be attached.



However, many believe this path is too narrow. This year's target for individual industry support funds utilizing indirect investment is only 460 billion won. The CEO of a bio company with experience in technology transfers worth several trillion won stated, "It's understandable to set a high bar for a high-risk industry, but since technology companies developing candidate substances are the driving force of the sector, there needs to be more consideration for opening the way to promising players."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing